,Canonical_Smiles,drug_name,drug_type,Label
0,c1ccc(C2(N3CCCCC3)CCCCC2)cc1,Phencyclidine,-,negative
1,NC(=O)CS(=O)C(c1ccccc1)c1ccccc1,Modafinil,HLp2-Inducer,positive
2,C[C@H](CCC(=O)O)[C@@H]1CC[C@H]2[C@H]3[C@H](CC[C@]12C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,chenodeoxycholic_acid,3A4-Substrate,negative
3,NC(=O)c1c(Cl)c(-c2cccnc2)n2c1C(O)CCC2,RPR_127025,3A4-Substrate,negative
4,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,Remoxipride,2D6-Substrate,negative
5,CC[Hg]Sc1ccccc1C(=O)[O-],Thiomersal,GST-Inhibitor,negative
6,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,Meloxicam,-,negative
7,CCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,Methylprednisolone Aceponate,3A4-Inducer,negative
8,NNC(=O)c1ccncc1,Isoniazid,2E1-Inducer,negative
9,C[C@@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,Clobetasol,1A2-Inhibitor,negative
10,CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C,Tinidazole,19A-Inhibitor,negative
11,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,Aceclofenac,-,negative
12,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,Fluconazole,HLp2-Inducer,positive
13,CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(C(C)C)cccc2C(C)C)c(C(C)C)c1,Avasimibe,-,negative
14,OC(c1ccccc1)(c1ccccc1)C1CCNCC1,Azacyclonol,-,negative
15,Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,Zolpidem,P450_HFLA-Substrate,negative
16,Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2,Pilsicainide,-,negative
17,NC(=O)N1c2ccccc2CC(=O)c2ccccc21,Oxcarbazepine,HLp2-Inducer,positive
18,C[C@H](COc1ccccc1)N(CCCl)Cc1ccccc1,Phenoxybenzamine,3A4-Substrate,negative
19,O=C1CC[C@@H](N2C(=O)c3ccccc3C2=O)C(=O)N1,Thalidomide,CP2CI-Substrate,negative
20,O=C(O)CCCC[C@@H]1CCSS1,Tioctic Acid,GST-Inducer,negative
21,CCCCCCCCCCCCCCCC(=O)O,palmitic_acid,2E1-Substrate,negative
22,COc1cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2cc1OC,Oxypertine,Canalicular_multispecific_organic_anion_transporter_2-Inducer,negative
23,CN(C)CCC=C1c2ccccc2COc2ccc(CC(=O)O)cc21,Olopatadine,-,negative
24,COc1ccc2c(CN)cc(=O)oc2c1,MAMC,2D6-Substrate,negative
25,O=C(O)c1ccccc1Nc1cccc(C(F)(F)F)c1,Flufenamic Acid,2E1-Inducer,negative
26,CN1/C(=C(/O)Nc2ccccn2)C(=O)c2sccc2S1(=O)=O,tenoxicam,2C9-Substrate,negative
27,C[C@H]1[C@H](NC(=O)C(=NOC(C)(C)C(=O)O)c2csc([NH3+])n2)C(=O)N1S(=O)(=O)[O-],Aztreonam,P450_HFLA-Substrate,negative
28,C=C[C@@H](N)CCC(=O)O,Vigabatrin,Proton_coupled_amino_acid_transporter_1-Substrate,negative
29,CC1=C(C)C(=O)C([C@H](CCCCCC(=O)O)c2ccccc2)=C(C)C1=O,Seratrodast,-,negative
30,Cc1cccc(C)c1,xylene_meta,2E1-Substrate,negative
31,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1,Mepyramine,2D6-Inhibitor,negative
32,NC(=O)C1(N2CCCCC2)CCN(CCCC(=O)c2ccc(F)cc2)CC1,Pipamperone,GST-Inducer,negative
33,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,Vinblastine,2D6-Substrate,negative
34,CSCC[C@H](N)C(=O)O,Methionine,GST-Inducer,negative
35,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,chlorpyrifos,2D6-Substrate,negative
36,CSc1ccc2c(c1)N(CC[C@H]1CCCCN1C)c1ccccc1S2,thioridazine_R,2E1-Substrate,negative
37,Oc1ccc(O)cc1,Hydroquinone,3A4-Substrate,negative
38,CC(C)(C)NC[C@H](O)c1cc(Cl)c(N)c(Cl)c1,Clenbuterol,1A2-Substrate,negative
39,Cc1ccccc1C,xylene_ortho,2E1-Substrate,negative
40,CN1C2CCC1CC(OC(=O)c1c[nH]c3ccccc13)C2,Tropisetron,2D6-Substrate,negative
41,CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21,Emetine,2D6-Substrate,negative
42,CC(C)C[C@@H](N(C)C)C1(c2ccc(Cl)cc2)CCC1,Sibutramine,-,negative
43,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,Levonorgestrel,19A-Inhibitor,negative
44,C=CC1(C)CO1,isoprene_epoxide_1,2E1-Substrate,negative
45,CC1(C)[C@@H](C=C(Cl)Cl)[C@H]1C(=O)OCc1cccc(Oc2ccccc2)c1,Permethrin,2B6-Inducer,negative
46,CCCCc1ncc(C=C(Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1,Eprosartan,-,negative
47,N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,Chlorhexidine,Methyltransferase-Inhibitor,negative
48,CC[C@H](Cc1ccc2c(c1)OCO2)NC,MBDB,2D6-Substrate,negative
49,CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12,halofantrine_R,2C8-Substrate,negative
50,CNCC[C@@H](Oc1ccccc1C)c1ccccc1,Atomoxetine,2D6-Inhibitor,negative
51,FCOC(C(F)(F)F)C(F)(F)F,Sevoflurane,2E1-Substrate,negative
52,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,Palonosetron,2D6-Substrate,negative
53,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)[C@@H]1c1cccc([N+](=O)[O-])c1,Manidipine,2D6-Inhibitor,negative
54,CCN(CCO)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12,Hydroxychloroquine,2D6-Inhibitor,negative
55,CCCCOC(=O)c1ccccc1C(=O)OCCCC,Dibutylphthalate,19A-Inducer,negative
56,CN[C@H](C)Cc1ccc2c(c1)OCO2,MDMA_R,2D6-Substrate,negative
57,CC(C(=O)O)c1ccc2c(c1)CC(=O)c1ccccc1S2,Zaltoprofen,-,negative
58,Cc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,dimemorfan,2D6-Substrate,negative
59,C[C@@H]1Cc2c(Cl)cc(C(=O)N[C@@H](Cc3ccccc3)C(=O)O)c(O)c2C(=O)O1,ochratoxin_A,2C9-Substrate,negative
60,O=C1C(=C2Nc3ccc(S(=O)(=O)[O-])cc3C2=O)Nc2ccc(S(=O)(=O)[O-])cc21,Indigo Carmine,Coumarin_7_hydroxylase-Inhibitor,negative
61,CSCCC(NC(=O)C(CC(C)C)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CC(=O)O)NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)O)C(C)O,Glucagon,GST-Inhibitor,negative
62,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1,Vecuronium,Methyltransferase-Inhibitor,negative
63,COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O,hesperetin,1A2-Substrate,negative
64,O=[P@@]1(N(CCCl)CCCl)OCCCN1CCCl,Trofosfamide,-,negative
65,CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,Itraconazole,19A-Inhibitor,negative
66,CSc1nc(-c2ccnc(NC(C)c3ccccc3)c2)c(-c2ccc(F)cc2)[nH]1,ML_3403,2D6-Substrate,negative
67,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,Anastrozole,19A-Inhibitor,negative
68,Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,Pemetrexed,Proton_coupled_folate_transporter-Substrate,negative
69,O=[As]1=[As](=O)O1,Arsenic Trioxide,1B1-Inhibitor,negative
70,COCCc1ccc(OC[C@H](O)CNC(C)C)cc1,Metoprolol,2D6-Substrate,negative
71,C[C@@H](N)Cc1ccccc1,Amfetamine,2D6-Inhibitor,negative
72,CCOc1ccc2ccc(=O)oc2c1,7_ethoxy_coumarin,2E1-Substrate,negative
73,CCN(CC)C(=S)[S-].[Na+],Ditiocarb sodium,-,negative
74,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)[C@@H]1c1ccccc1[N+](=O)[O-],Nisoldipine,P450_HFLA-Substrate,negative
75,Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1,Zalcitabine,P450_HFLA-Substrate,negative
76,Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,Folic Acid,2E1-Substrate,negative
77,CNC(=O)Oc1cccc2c1OC(C)(C)C2,carbofuran,2D6-Substrate,negative
78,CCCCNC(C)Cc1ccc(OC)cc1,4_methoxy_N_butylamphetamine,2D6-Substrate,negative
79,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,Benazepril,Aldosterone_synthase_ALDOS_Aldosterone_synthesizing_enzyme_Steroid_18_hydroxylase-Inhibitor,negative
80,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@H]2O[C@@H](C)C[C@@H](N(C)C)[C@@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Erythromycin,P450_HFLA-Substrate,negative
81,COc1ccc2ccc(=O)oc2c1,7_methoxy_coumarin,2E1-Substrate,negative
82,Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C,Sulfamoxole,-,negative
83,Oc1ccc(C(c2ccc(O)cc2)C(Cl)(Cl)Cl)cc1,bis_OH_methoxychlor,3A4-Substrate,negative
84,CN(C)N/N=C1\N=CN=C1C(N)=O,dacarbazine,2E1-Substrate,negative
85,CCN(CC)CCCN(c1ccccc1)C1Cc2ccccc2C1,Aprindine,2D6-Substrate,negative
86,CN[C@H](C)Cc1ccccc1,methamphetamine_R,2D6-Substrate,negative
87,CC(C)n1c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,fluvastatin,2D6-Substrate,negative
88,O=C([O-])O,Sodium Bicarbonate,Electroneutral_sodium_bicarbonate_exchanger_1-Substrate,negative
89,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,Ketoprofen,GST-Inhibitor,negative
90,CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)[C@@H](CO)c1ccccc1)C2,Atropine,1A2-Inhibitor,negative
91,Cc1ccc(C(=CCN2CCCC2)c2ccccn2)cc1,Triprolidine,2D6-Inhibitor,negative
92,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1,cerivastatin,3A4-Substrate,negative
93,COc1cc2c(c(OC)c1OC)-c1c(cc(OC)c(OC)c1OC)C[C@@H](C)[C@@H](C)C2,deoxy_schizandrin,3A4-Substrate,negative
94,C#C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)C1=C(CC(=O)CC1)C[C@H]3C,Tibolone,19A-Inhibitor,negative
95,c1ccc2c(c1)Sc1ccccc1N2C[C@H]1CN2CCC1CC2,Mequitazine,2D6-Substrate,negative
96,CO[C@H](C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1,Plicamycin,Methyltransferase-Inhibitor,negative
97,CCc1cccc2cc([C@H](O)CNC(C)(C)C)oc12,bufuralol_R,2D6-Substrate,negative
98,Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1,Triamterene,1A2-Inhibitor,negative
99,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,Nelfinavir,P450_HFLA-Inhibitor,negative
100,NCCc1c[nH]cn1,Histamine,2E1-Inducer,negative
101,CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O,Phenoxymethylpenicillin,3A4-Inducer,negative
102,COc1ccc(OC)c([C@@H](O)[C@@H](C)N)c1,Methoxamine,Solute_carrier_family_12_member_2-Inducer,negative
103,CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1,Chlordiazepoxide,2D6-Substrate,negative
104,CN(C)Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,Adinazolam,-,negative
105,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1,Parecoxib,2D6-Inhibitor,negative
106,C[C@H](NCCc1ccc(O)cc1)[C@H](O)c1ccc(O)cc1,Ritodrine,SUL-Substrate,negative
107,CN(C)CCC=C1c2ccccc2Sc2ccc(Cl)cc21,Chlorprothixene,3A4-Substrate,negative
108,Clc1ccc([C@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1,Isoconazole,19A-Inhibitor,negative
109,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(C=NNO)cc1)C1CCCCC1,Ximelagatran,2C9-Substrate,negative
110,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,Quinidine,2E1-Substrate,negative
111,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1,Clindamycin,-,negative
112,Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,Sulfamethoxazole,-,negative
113,Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,Nevirapine,2D6-Substrate,negative
114,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,Clozapine,2E1-Inhibitor,negative
115,NCC(=O)CCC(=O)O,Aminolevulinic Acid,Solute_carrier_family_15_member_2-Substrate,negative
116,Nc1nc2cc(Cl)ccc2o1,Zoxazolamine,-,negative
117,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,Azacitidine,Methyltransferase-Inhibitor,negative
118,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,Mosapride,-,negative
119,CC(C)CCON=O,Amyl Nitrite,GST-Substrate,negative
120,O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1,Bromperidol,2D6-Substrate,negative
121,[Cl-].[Na+],Sodium Chloride,2E1-Inducer,negative
122,NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NC(Cc1ccccc1)NS2(=O)=O,Bendroflumethiazide,Methyltransferase-Inhibitor,negative
123,C[C@H](CN(C)C)CN1c2ccccc2CCc2ccccc21,Trimipramine,2D6-Substrate,negative
124,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21,Norfloxacin,P450_HFLA-Inhibitor,negative
125,Oc1ccccc1-c1ccccc1,O_phenylphenol,2E1-Substrate,negative
126,CCOCn1c(Cc2ccccc2)c(C(C)C)c(=O)[nH]c1=O,Emivirine,-,negative
127,C/C=C/C,trans_2_butene,2E1-Substrate,negative
128,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21,Pefloxacin,-,negative
129,Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,Lansoprazole,4A11-Inducer,negative
130,COCc1c(C(C)C)nc(C(C)C)c(C=C[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1,Cerivastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
131,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,Bromocriptine,-,negative
132,CO[C@H]1C=CO[C@]2(C)Oc3c(C)c(O)c4c(O)c(cc(O)c4c3C2=O)NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,Rifamycin,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
133,O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3[C@H]2C1,Praziquantel,P450_HFLA-Substrate,negative
134,CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(C(C)=O)c1,Celiprolol,Solute_carrier_organic_anion_transporter_family_member_1A2-Substrate,negative
135,COc1cc(CNC(=O)CCCCC=CC(C)C)ccc1O,Capsaicin,2E1-Substrate,negative
136,CCOc1ccc2cc(C#N)c(=O)oc2c1,3_cyano_7_ethoxycoumarin,2E1-Substrate,negative
137,CCC1C2CC3C4N(C)c5ccccc5C45CC(C2C5O)N3C1O,Ajmaline,2D6-Inhibitor,negative
138,O=C(O)c1cccnc1Nc1cccc(C(F)(F)F)c1,Niflumic Acid,Monocarboxylate_transporter_1-Inhibitor,negative
139,CC(C)c1nc(CN(C)C(=O)N[C@@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,Ritonavir,HLp2-Inducer,positive
140,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,Pazopanib,3A4-Inhibitor,negative
141,CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,Terconazole,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
142,CCC(=C(CC)c1ccc(O)cc1)c1ccc(O)cc1,Diethylstilbestrol,19A-Inducer,negative
143,COc1ccc(CC(C)N)cc1,4_methoxy_amphetamine,2D6-Substrate,negative
144,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,Zafirlukast,2E1-Inhibitor,negative
145,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1_alpha_hydroxy_vitamin_D3,3A4-Substrate,negative
146,O=C1CC(=O)N(c2ccccc2)c2cc(Cl)ccc2N1,N_desmethyl_clobazapam,2C19-Substrate,negative
147,CN1CCN=C(c2ccccc2)c2cc(Cl)ccc21,Medazepam,2E1-Inhibitor,negative
148,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,Atorvastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
149,COc1ccc(-c2cc(=O)c3c(OC)c(OC)c(OC)c(OC)c3o2)cc1,tangeretin,2D6-Substrate,negative
150,ClC1=C(Cl)C2(Cl)C3C4CC(C5OC45)C3C1(Cl)C2(Cl)Cl,Dieldrin,-,negative
151,CCN(CC)CC#CCOC(=O)[C@@](O)(c1ccccc1)C1CCCCC1,Oxybutynin,2D6-Inhibitor,negative
152,COc1ccc(C(c2ccc(OC)cc2)C(Cl)(Cl)Cl)cc1,methoxychlor,2C19-Substrate,negative
153,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1,Mirtazapine,2D6-Inhibitor,negative
154,CC(C(=O)c1ccc2c(c1)OCO2)N1CCCC1,MDPPP,2D6-Substrate,negative
155,CCNC(C)Cc1ccccc1,N_ethyl_amphetamine,2D6-Substrate,negative
156,CCC[C@@H](C)C1(CC)C(=O)NC(=O)NC1=O,Pentobarbital,-,negative
157,NC(N)=Nc1nc(CSCCN=CNS(=O)(=O)c2ccc(Br)cc2)cs1,Ebrotidine,-,negative
158,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC=Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,Pranidipine,-,negative
159,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O,Diflunisal,UGT-Substrate,negative
160,CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,Bupivacaine,2D6-Substrate,negative
161,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,Amprenavir,2D6-Substrate,negative
162,c1ccc([C@H]2CN3CCSC3=N2)cc1,Levamisole,GST-Inducer,negative
163,CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1,Atenolol,3A4-Substrate,negative
164,CCCC1(CCc2ccccc2)CC(O)=C(C(CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1,Tipranavir,-,negative
165,C[C@@H]1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23,Flumequine,2E1-Inhibitor,negative
166,CC(C)c1nc(COC(N)=O)n(Cc2ccncc2)c1Sc1cc(Cl)cc(Cl)c1,Capravirine,-,negative
167,Clc1cccc(Cl)c1NC1=NCCN1,Clonidine,19A-Inducer,negative
168,Cc1cc(-c2ccccc2)nnc1NCCN1CCOCC1,Minaprine,2D6-Substrate,negative
169,CCOP(=S)(OCC)SCSCC,phorate,2C19-Substrate,negative
170,CN[C@@H](C)[C@H](O)c1ccccc1,Ephedrin,SUL-Substrate,negative
171,CCN[C@@H]1C[C@@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,Dorzolamide,2E1-Substrate,negative
172,O=C1C[C@H](c2ccc(O)cc2)Oc2cc(O)cc(O)c21,naringenin,1A2-Substrate,negative
173,COc1cc2c(CCN3CCN(c4cccc(Cl)c4C)CC3)nn(Cc3c[nH]cn3)c2cc1OC,DY_9760e,2D6-Substrate,negative
174,Oc1nc2cc(Cl)ccc2o1,Chlorzoxazone,2E1-Inhibitor,negative
175,O=C(O)c1ccccc1O,Salicylic Acid,2E1-Inducer,negative
176,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,Etoricoxib,2E1-Inhibitor,negative
177,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Gemcitabine,Multidrug_resistance_associated_protein_5-Inducer,negative
178,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1,Oxaprozin,2C9-Substrate,negative
179,O=[P@]1(NCCCl)OCCCN1CCCl,Ifosfamide,CP2CI-Substrate,negative
180,CC[C@@]1(c2ccc(N)cc2)CCC(=O)NC1=O,Aminogluthetimide,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inhibitor,negative
181,Clc1ccc(Cl)c(-c2cc(Cl)c(Cl)cc2Cl)c1,PCB_101,3A4-Substrate,negative
182,N#N,Nitrogen,Solute_carrier_family_15_member_1-Substrate,negative
183,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1,Sertindole,2D6-Substrate,negative
184,CN1CCC[C@H](n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,Azelastine,2E1-Inhibitor,negative
185,CN1C(=O)NC(=O)[C@@](C)(C2=CCCCC2)C1=O,hexobarbital_R,2C19-Substrate,negative
186,C/C=C\C,cis_2_butene,2E1-Substrate,negative
187,CN(C)CCC=C1c2ccccc2CCc2ccccc21,Amitriptyline,2E1-Substrate,negative
188,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,Cyproterone,19A-Inhibitor,negative
189,CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1,Fesoterodine,2D6-Substrate,negative
190,C=CCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_12,3A4-Substrate,negative
191,COc1ccc2c(C[n+]3ccccc3)cc(=O)oc2c1,MMPyrC,2D6-Substrate,negative
192,COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12,Carvedilol,2E1-Substrate,negative
193,O=C(CCCN1CCC(O)(c2cccc(C(F)(F)F)c2)CC1)c1ccc(F)cc1,Trifluperidol,2D6-Substrate,negative
194,CCN(CC)CCc1nc(-c2ccccc2)no1,Oxolamine,1B1-Inducer,negative
195,CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1,Zaleplon,P450_HFLA-Substrate,negative
196,OCCCOc1cccc(CN2CCCCC2)c1,roxatidine_m5,2D6-Substrate,negative
197,CCCCCN(CCCCC)N=O,NN_diamyl_nitrosoamine,2E1-Substrate,negative
198,N=C(N)NC(=O)c1nc(Cl)c(N)nc1N,Amiloride,Solute_carrier_family_22_member_1-Inhibitor,negative
199,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO,Betamethasone,-,negative
200,C[C@@H](NC(=Nc1ccncc1)NC#N)C(C)(C)C,Pinacidil,2D6-Substrate,negative
201,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O)C=CC=CC[C@@H](C)OC(=O)C[C@H]1OC(C)=O,Josamycin,-,negative
202,CC(C)=O,Acetone,-,negative
203,CCCCCCCCC=CCCCCCCCC(=O)O,Monoethanolamine Oleate,2E1-Substrate,negative
204,Cc1c(C)c2c(c(C)c1O)CC[C@](C)(COc1ccc(C[C@H]3SC(=O)NC3=O)cc1)O2,troglitazone,2C8-Substrate,negative
205,COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1,Sulfadimethoxine,-,negative
206,COc1ccc2c(c1)N(C[C@H](C)CN(C)C)c1ccccc1S2,Levomepromazine,2E1-Inhibitor,negative
207,CNC(=O)Oc1cc(C)c(SC)c(C)c1,Methiocarb,2D6-Substrate,negative
208,CCOC(=O)[C@@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,Enalapril,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
209,CN1C(=O)CC(=O)N(c2ccc(O)cc2)c2cc(Cl)ccc21,4prime_hydroxy_clobazam,2C19-Substrate,negative
210,NC(N)=O,Carbamide,2E1-Inducer,negative
211,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Prednisone,-,negative
212,COc1ccc(CN2CCNCC2)c(OC)c1OC,Trimetazidine,-,negative
213,Cl,Hydrochloric Acid,2D6-Inhibitor,negative
214,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,Ropivacaine,2D6-Substrate,negative
215,CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21,Nalidixic acid,-,negative
216,CN1C(CC(=O)c2ccccc2)CCCC1CC(O)c1ccccc1,Lobeline,-,negative
217,CC(C)n1c(C=C[C@H](O)C[C@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,Fluvastatin,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
218,CCCCN(CCCC)N=O,NN_dibutyl_nitrosoamine,2E1-Substrate,negative
219,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,bortezomib,2D6-Substrate,negative
220,O=C(OC[C@H](O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12,Glafenine,ATP_binding_cassette_sub_family_G_member_2-Inhibitor,negative
221,CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12,Zolmitriptan,-,negative
222,CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21,temazepam,2C19-Substrate,negative
223,COc1c(C)c2c(c(O)c1CC=C(C)CCC(=O)O)C(=O)OC2,Mycophenolic Acid,Solute_carrier_family_22_member_6-Substrate,negative
224,Clc1ccc([C@@H](Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1,Tioconazole,19A-Inhibitor,negative
225,Cc1cccc(CN2CCN([C@@H](c3ccccc3)c3ccc(Cl)cc3)CC2)c1,Meclozin,1A2-Inhibitor,negative
226,NCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,Norfluoxetine,2D6-Substrate,negative
227,CSCC[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)O,Corticotropin,SUL-Inducer,negative
228,CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,warfarin_S,2C19-Substrate,negative
